Ratings Thermo Fisher Scientific Inc. Buenos Aires S.E.

Equities

TMO

ARBCOM4601F7

End-of-day quote Buenos Aires S.E. Other stock markets 06:00:00 2024-06-06 pm EDT			5-day change	1st Jan Change
34,744 ^ARS	+1.31%		+8.27%	+48.52%

Jun. 05	Thermo Fisher Scientific Insider Sold Shares Worth $11,374,358, According to a Recent SEC Filing	MT
Jun. 03	Thermo Fisher Scientific Introduces Innovative Mass Spectrometer to Advance Clinical Research	CI

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The company returns high margins, thereby supporting business profitability.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

The company is in debt and has limited leeway for investment
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 36.49 times its estimated earnings per share for the ongoing year.
The company's "enterprise value to sales" ratio is among the highest in the world.
The company appears highly valued given the size of its balance sheet.
The company is highly valued given the cash flows generated by its activity.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
For the past year, analysts have significantly revised downwards their profit estimates.
Over the past twelve months, analysts' opinions have been revised negatively.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
THERMO FISHER SCIENTIFIC INC.	+48.52%	222B	-
DANAHER CORPORATION	+13.72%	195B	B-
INTUITIVE SURGICAL, INC.	+23.79%	148B	B-
BOSTON SCIENTIFIC CORPORATION	+33.39%	113B	A-
SIEMENS HEALTHINEERS AG	+4.75%	66.45B	A-
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+3.16%	50.03B	B+
AGILENT TECHNOLOGIES, INC.	-4.35%	38.8B	A
GE HEALTHCARE TECHNOLOGIES INC.	-1.27%	34.85B	-
RESMED, INC.	+22.61%	30.98B	B+
PHILIPS NV	+19.58%	24.7B	B

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes